981 results on '"Golemis, Erica A."'
Search Results
2. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
3. Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer
4. Loss of Pkd1 limits susceptibility to colitis and colorectal cancer
5. Correction: Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing
6. Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing
7. Patterns of Ciliation and Ciliary Signaling in Cancer
8. Intrapancreatic fat, pancreatitis, and pancreatic cancer
9. eLife assessment: circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA
10. FIGURE 4 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
11. Figure S3 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
12. FIGURE 6 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
13. FIGURE 3 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
14. Supplementary Data from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
15. TABLE 1 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
16. FIGURE 5 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
17. Data from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
18. FIGURE 1 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
19. FIGURE 2 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
20. NEDD9 sustains hexokinase expression to promote glycolysis
21. Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers
22. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.
23. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer
24. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression
25. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors
26. Targeting the ErbB Family in Head and Neck Cancer
27. Overview: The Pathobiology of Head and Neck Cancer
28. eLife assessment: circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA
29. Methods | Two-Hybrid Protein–Protein Interactions
30. Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6).
31. Abstract PO-032: Association of a polymorphic variant in JMJD1C with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma
32. Abstract PO-024: Analysis of the NOTCH pathway in HNSCC: A target with a wide prognostic and therapeutic potential
33. Identification of the KRIT1 Protein by LexA-Based Yeast Two-Hybrid System
34. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack
35. Patterns of Ciliation and Ciliary Signaling in Cancer
36. NEDD9
37. Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
38. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer
39. Simian Virus 40 Large T Antigen Targets the Spindle Assembly Checkpoint Protein Bub1
40. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer
41. EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer
42. Overview: The Pathobiology of Head and Neck Cancer
43. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-Dependent Transformation Phenotypes in Human Cancer Cells
44. Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
45. PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization
46. Musashi-2 (MSI2) regulation of DNA damage response in lung cancer
47. MED1, a Novel Human methyl-CpG-binding Endonuclease, Interacts with DNA Mismatch Repair Protein MLH1
48. Ciliary signalling in cancer
49. NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice
50. Abstract 542: Synthetic lethal targeting of AURKA in head and neck squamous cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.